Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have earned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company. Aeglea Bio Therapeutics’ rating score has declined by 33% from three months ago as a result of a number of analysts’ ratings changes.
Brokers have set a one year consensus price objective of $18.00 for the company and are predicting that the company will post ($0.54) EPS for the current quarter, according to Zacks. Zacks has also assigned Aeglea Bio Therapeutics an industry rank of 185 out of 265 based on the ratings given to its competitors.
Several research analysts recently issued reports on AGLE shares. Needham & Company LLC upped their target price on Aeglea Bio Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, March 14th. Zacks Investment Research lowered Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $18.00 target price on shares of Aeglea Bio Therapeutics in a research report on Wednesday, March 14th.
A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in Aeglea Bio Therapeutics by 150.8% during the 4th quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 19,300 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Aeglea Bio Therapeutics by 0.6% in the fourth quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock valued at $7,539,000 after purchasing an additional 8,372 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Aeglea Bio Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 12,966 shares during the period. 47.43% of the stock is currently owned by institutional investors.
WARNING: This news story was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.wkrb13.com/2018/04/01/zacks-aeglea-bio-therapeutics-inc-agle-given-average-recommendation-of-strong-buy-by-brokerages.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.